Class action lawsuits against CBD manufacturers are emerging at an increasing rate due to a lack of FDA framework, along with a surge of cannabis products entering the market. Loeb & Loeb litigation associate Christopher Binns highlights the reasons behind the complaints and what their implications mean for cannabis companies and the FDA alike.
Click here to read the full article on the Law360 website.